BC Extra | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
BC Extra | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
BioCentury | Jun 9, 2017

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
BC Extra | Jun 1, 2017
Financial News

Bicycle closes £40 million series B

Bicycle Therapeutics Ltd. (Cambridge, U.K.) raised £40 million ($51.3 million) in a series B round led by new investor Vertex Ventures HC. New investors Cambridge Innovation Capital and Longwood Fund also participated, as did existing...
BioCentury | Oct 19, 2015

Funding cycles

After five years of drip feeding Bicycle Therapeutics Ltd. , the investor syndicate has installed new CEO Kevin Lee into a company that's fully funded to advance programs into the clinic. The VCs think the measured...
Items per page:
1 - 5 of 5